Zhuo-Ying Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhuo-Ying Luo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Hao-Yang Huang
14 shared publications- Jia-Yu Zhou
Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China
14 shared publications - Liang-Ru Ke
Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China
14 shared publications - Lin-Quan Tang
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
14 shared publications - Lu-Jun Han
Department of Radiology, Sun Yat-Sen University Cancer Centre, Guangzhou, China
14 shared publications - Shan-Shan Guo
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
14 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Figure 1. Kaplan-Meier analyses of the efficacy population.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Figure 1. Kaplan-Meier analyses of the efficacy population.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 4. Summary of diagnosis of residual nasopharyngeal carcinoma.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 4. Summary of diagnosis of residual nasopharyngeal carcinoma.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Purpose:Patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment have poor prognoses. In this trial, we aimed to assess the efficacy and safety of capecitabine maintenance therapy in patients with residual nasopharyngeal carcinoma.Patients and Methods:This open-label, single-arm, phase II trial was conducted at Sun Yat-sen University Cancer Center. We recruited patients of 18 to 70 years of age with an Eastern Cooperative Oncology Group performance status score of 0 to 1, histopathologically or cytologically confirmed nasopharyngeal carcinoma (without distant metastasis), who had residual disease after receiving definitive treatment. Patients received 1 year of capecitabine maintenance therapy. The primary endpoint was 2-year progression-free survival.Results:Between January 1, 2019, and December 30, 2022, 111 patients were recruited and commenced capecitabine maintenance therapy for 1 year. After a median follow-up duration of 34.8 months (IQR = 30.5–45.2), progression-free survival was 92% at 1 year, 86% at 2 years, and 81% at 3 years. Adverse events were reported in 97.3% of patients. Hand-foot syndrome was the most common adverse event (59.5%). In addition, 28.7% of patients experienced grade 3 treatment-related adverse events, the most common of which was hand-foot syndrome (7.2%); no grade 4 or 5 adverse events were recorded. A total of 72.1% of patients received the full dosage of capecitabine, and 76.6% of patients completed the 1-year capecitabine maintenance therapy.Conclusions:The antitumor efficacy of capecitabine maintenance therapy is promising, and the safety profile is manageable in patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Purpose:Patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment have poor prognoses. In this trial, we aimed to assess the efficacy and safety of capecitabine maintenance therapy in patients with residual nasopharyngeal carcinoma.Patients and Methods:This open-label, single-arm, phase II trial was conducted at Sun Yat-sen University Cancer Center. We recruited patients of 18 to 70 years of age with an Eastern Cooperative Oncology Group performance status score of 0 to 1, histopathologically or cytologically confirmed nasopharyngeal carcinoma (without distant metastasis), who had residual disease after receiving definitive treatment. Patients received 1 year of capecitabine maintenance therapy. The primary endpoint was 2-year progression-free survival.Results:Between January 1, 2019, and December 30, 2022, 111 patients were recruited and commenced capecitabine maintenance therapy for 1 year. After a median follow-up duration of 34.8 months (IQR = 30.5–45.2), progression-free survival was 92% at 1 year, 86% at 2 years, and 81% at 3 years. Adverse events were reported in 97.3% of patients. Hand-foot syndrome was the most common adverse event (59.5%). In addition, 28.7% of patients experienced grade 3 treatment-related adverse events, the most common of which was hand-foot syndrome (7.2%); no grade 4 or 5 adverse events were recorded. A total of 72.1% of patients received the full dosage of capecitabine, and 76.6% of patients completed the 1-year capecitabine maintenance therapy.Conclusions:The antitumor efficacy of capecitabine maintenance therapy is promising, and the safety profile is manageable in patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 3. Administration of concurrent chemoradiotherapy.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 3. Administration of concurrent chemoradiotherapy.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 7. Subsequent treatments of patients who did experienced disease progression events.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 7. Subsequent treatments of patients who did experienced disease progression events.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 2. Administration of upfront induction chemotherapy.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 2. Administration of upfront induction chemotherapy.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 1. Location of residual nasopharyngeal carcinoma.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 1. Location of residual nasopharyngeal carcinoma.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 8. Compliance to treatment.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 8. Compliance to treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 5. Representativeness of study participants.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Table 5. Representativeness of study participants.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Method 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Method 1. Radiological diagnostic criteria of residual nasopharyngeal carcinoma.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Supplementary Method 1. Radiological diagnostic criteria of residual nasopharyngeal carcinoma.